Latest Recurring Revenue News

Clever Culture Systems posted a $1.32 million loss for the half year ending December 2025, reflecting a strategic shift and reduced government grants. Despite this, the company strengthened its cash position, repaid government debt, and grew its APAS Independence instrument footprint globally.

Kinatico Ltd reports robust H1 FY26 results, driven by a 49.5% surge in SaaS revenue and the launch of its AI-powered Kinatico Compliance platform, significantly broadening its addressable market.

Centrepoint Alliance reports a 17% rise in normalised EBITDA for H1 FY26 and announces a strategic divestment of its lending aggregation business to Astute Financial Management, expected to boost annual EBITDA by $0.4 million from FY27.

Asset Vision has reported a robust 38% increase in annual recurring revenue to $5.2 million in the first half of FY26, underpinned by new council contracts and AI-driven platform upgrades. The company’s positive cash EBITDA and strategic focus on scalable growth signal strong momentum in the critical infrastructure SaaS market.

Asset Vision Co Limited reported a 27% increase in revenue to $3.06 million for the half-year ended December 2025, yet recorded a net loss of $54,052 due to deliberate investments in growth and product development.

Adherium Limited launches a A$7.52 million equity raising to fund commercial expansion of its Hailie SmartInhaler remote patient monitoring platform targeting asthma and COPD patients in the US. The company aims to scale patient numbers and progress towards value-based care contracts with major insurers.

The week was split between big earnings reactions and small-cap rocks-and-rigs rallies. Pro Medicus sank despite record numbers, while a handful of explorers jumped on fresh discoveries and policy wins.

Takeover chatter lit up Pepper Money, while Identitii ran hard after a regulator stepped in. At the other end, AMP slid despite higher profit, as investors weighed leadership change and legal costs.

Healthcare stocks split into two stories this week: big names sold off hard, while a few small caps ran on clear news. The biggest moves came from a sharp fall in Pro Medicus and Cochlear, while Noxopharm jumped after a top-tier journal publication.

Big moves came from disclosure drama, CEO change news, and one standout software upgrade. While several stocks jumped on results, a few gaps couldn’t hold as traders sold into early strength.

Amaero Ltd reported a remarkable 367% revenue increase to A$7.76 million for H1 FY2026, supported by a $50 million capital raise and exclusive supply agreements with industry leaders. Despite widening losses, the company is accelerating capacity expansion and securing key partnerships in aerospace and defence.

Microequities Asset Management Group Limited has reported a robust half-year performance with a 41% jump in profit after tax and record funds under management reaching $657 million. The company also announced a 21% increase in its fully franked interim dividend.